Literature DB >> 1972217

HTLV-I/II seropositivity and death from AIDS among HIV-1 seropositive intravenous drug users.

J B Page1, S H Lai, D D Chitwood, N G Klimas, P C Smith, M A Fletcher.   

Abstract

In a prospective study of street-recruited intravenous drug users (IVDUs) in Miami, Florida, USA, 107 (46.5%) of 230 IVDUs were infected with HIV-1. Of these HIV-1 seropositive individuals, 23 were also infected with human T-lymphotropic virus type I or II (HTLV-I/II). To test the hypothesis that HTLV-I/II infection has an effect on the survival of HIV-1 seropositive IVDUs, various baseline clinical and laboratory HIV-1 related indices in HTLV-I/II positive and negative groups were compared. Life table analysis and Cox's proportional hazards model were used to estimate the potential effect of HTLV-I/II infection on the survival patterns of people infected with HIV-1. IVDUs infected with both viruses were three times more likely to die from AIDS during follow-up than were those infected with HIV-1 only. This finding suggests that HTLV-I/II seropositivity may adversely affect the clinical outcome of HIV-1 seropositive patients.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1972217     DOI: 10.1016/0140-6736(90)91456-k

Source DB:  PubMed          Journal:  Lancet        ISSN: 0140-6736            Impact factor:   79.321


  27 in total

1.  Injection drug use, mortality, and the AIDS epidemic.

Authors:  P A Selwyn
Journal:  Am J Public Health       Date:  1991-10       Impact factor: 9.308

2.  Predictors of survival in human immunodeficiency virus type 1-seropositive intravenous drug users.

Authors:  J B Page; S Lai; M A Fletcher; R Patarca; P C Smith; H C Lai; N G Klimas
Journal:  Clin Diagn Lab Immunol       Date:  1996-01

3.  Distress, denial, and low adherence to behavioral interventions predict faster disease progression in gay men infected with human immunodeficiency virus.

Authors:  G Ironson; A Friedman; N Klimas; M Antoni; M A Fletcher; A Laperriere; J Simoneau; N Schneiderman
Journal:  Int J Behav Med       Date:  1994

4.  Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus.

Authors:  M Torten; M Franchini; J E Barlough; J W George; E Mozes; H Lutz; N C Pedersen
Journal:  J Virol       Date:  1991-05       Impact factor: 5.103

5.  HTLV-II does not adversely affect the natural history of HIV-1 infection in intravenous drug users.

Authors:  G Magnani; G Elia; C Casoli; C Calzetti; A Degli Antoni; F Fiaccadori
Journal:  Infection       Date:  1995 Jan-Feb       Impact factor: 3.553

6.  Protection of rabbits against HTLV-II infection with a synthetic peptide corresponding to HTLV-II neutralization region.

Authors:  N Kariya; K Hayashi; H Hoshino; Y Tanaka; T R Koirala; N Ohara; K Miyamoto; T Akagi
Journal:  Arch Virol       Date:  1996       Impact factor: 2.574

7.  Strong trans activation of the human cytomegalovirus major immediate-early enhancer by p40tax of human T-cell leukemia virus type I via two repetitive tax-responsive sequence elements.

Authors:  H Moch; D Lang; T Stamminger
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

Review 8.  Pathogenesis of human immunodeficiency virus infection.

Authors:  J A Levy
Journal:  Microbiol Rev       Date:  1993-03

9.  Induction of antibody responses that neutralize human T-cell leukemia virus type I infection in vitro and in vivo by peptide immunization.

Authors:  Y Tanaka; R Tanaka; E Terada; Y Koyanagi; N Miyano-Kurosaki; N Yamamoto; E Baba; M Nakamura; H Shida
Journal:  J Virol       Date:  1994-10       Impact factor: 5.103

10.  Isolation of a human T-lymphotropic virus type I strain from Australian aboriginals.

Authors:  I Bastian; J Gardner; D Webb; I Gardner
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.